市場調查報告書

疫苗的全球市場:各技術,各疾病,各給藥途徑,各類型患者,各地區的市場規模,趨勢分析,市場佔有率,預測:2020年∼2027年

Global Vaccine Market Size, by Technology, Disease, Route, Patient, By Region, Trend Analysis, Competitive Market Share & Forecast, 2020-2027

出版商 Blueweave Consulting & Research Private Limited 商品編碼 951538
出版日期 內容資訊 英文 175 Pages
商品交期: 最快1-2個工作天內
價格
疫苗的全球市場:各技術,各疾病,各給藥途徑,各類型患者,各地區的市場規模,趨勢分析,市場佔有率,預測:2020年∼2027年 Global Vaccine Market Size, by Technology, Disease, Route, Patient, By Region, Trend Analysis, Competitive Market Share & Forecast, 2020-2027
出版日期: 2020年05月01日內容資訊: 英文 175 Pages
簡介

疫苗,是讓人接種衰弱的病原體以促進抗體的形成,除了脊髓灰質炎和天花等預防發揮很大的效果,也用於癌症的免疫療法。市場擴大的原動力,是是對伊波拉出血熱、流感、豬流感、肝炎、結核、白喉、腦膜炎性疾病和肺炎球菌性疾病等的感染疾病的擴大,技術性高的疫苗,疫苗輸送設備的進步,疫苗接種計劃的擴大等要素。另一方面反對疫苗接種的運動也持續著,世界衛生組織(WHO)指出,逃避疫苗接種是公共衛生的威脅的前10名之一。

本報告提供全球疫苗市場調查,產業的考察,市場概要,各地區的分析,主要企業的簡介等資訊。

目錄

第1章 調查架構

第2章 調查手法

第3章 摘要整理

第4章 產業的考察

  • 產業的價值鏈分析
  • DROC分析
    • 成長要素
    • 阻礙因素
    • 市場機會
    • 課題
  • 技術形勢/最新趨勢
  • 法律規範
  • 各公司的市場佔有率分析
  • 波特的五力分析
  • 新型冠狀病毒感染疾病(COVID 19)的影響

第5章 全球市場概要

  • 市場規模與預測:2016∼2026年
  • 市場佔有率與預測
    • 各技術
      • 活病毒疫苗
      • 類毒素
      • 重組疫苗
    • 各疾病
      • 肺炎球菌
      • 流感
      • DTP
      • 輪狀病毒
      • TT
      • 脊髓灰質炎
      • MMR
      • 水痘
      • 登革熱
      • TB,
      • 帶狀皰疹
      • 狂犬病(恐水症)
    • 各給藥途徑
      • IM
      • SC
      • ID
      • 口服
    • 各類型患者
      • 兒童
      • 成人
    • 各地區
      • 北美
      • 歐洲
      • 亞太地區
      • 南美
      • 中東、非洲

第6章 北美市場

  • 市場規模與預測:2016∼2026年
  • 市場佔有率與預測
    • 各技術
    • 各疾病
    • 各給藥途徑
    • 各類型患者
    • 各國
      • 美國
      • 加拿大

第7章 歐洲市場

  • 市場規模與預測:2016∼2026年
  • 市場佔有率與預測
    • 各技術
    • 各疾病
    • 各給藥途徑
    • 各類型患者
    • 各國
      • 德國
      • 英國
      • 法國
      • 義大利
      • 西班牙
      • 其他

第8章 亞太地區市場

  • 市場規模與預測:2016∼2026年
  • 市場佔有率與預測
    • 各技術
    • 各疾病
    • 各給藥途徑
    • 各類型患者
    • 各國
      • 印度
      • 中國
      • 日本
      • 韓國
      • 其他

第9章 南美市場

  • 市場規模與預測:2016∼2026年
  • 市場佔有率與預測
    • 各技術
    • 各疾病
    • 各給藥途徑
    • 各類型患者
    • 各國

第10章 中東及非洲市場

  • 市場規模與預測:2016∼2026年
  • 市場佔有率與預測
    • 各技術
    • 各疾病
    • 各給藥途徑
    • 各類型患者
    • 各國

第11章 企業簡介 (公司概要,財務矩陣,主要產品情勢,主要人物,主要的競爭企業,聯絡原住所,策略性展望)*

  • Glaxosmithkline PLC
  • Pfizer, Inc
  • Merck & Co., Inc
  • Sanofi Pasteur SA
  • CSL Limited
  • Emergent Biosolutions, Inc
  • Johnson & Johnson
  • Astrazeneca
  • Serum Institute of India Pvt., LTD
  • Bavarian Nordic
  • Mitsubishi Tanabe Pharma Corporation
  • Daiichi Sankyo Company, Limited
  • Panacea Biotec, LTD
  • Biological E
  • Bharat Biotech .
  • Other Prominent Players
目錄
Product Code: BWC20079

Vaccines, also known as immunizations, vaccinate a debilitating form of illness into a person, so the body starts creating antibodies or protection besides the disease. Real vaccination has eliminated several conditions, like polio and smallpox, with high death rates. The U.S. Food and Drug Administration newly permitted the first vaccine for dengue disease, the foremost cause of illness amid people existing in the tropics and subtropics. Vaccines can also be used after contamination occurs as a therapeutic. This kind of action has lately developed prevalent for use in immuno-oncology for cancer, making up 15 percent of immunotherapies in 2014. The vaccine market lasts to show development, although the anti-vaccine movement. In the U.S., this drive has created an atmosphere of suspicion around vaccines, despite growing indications of vaccines' safety and efficacy. The World Health Organization has named vaccine hesitancy as one of the top ten threats fronting public health this year.

The high occurrence rate of infectious diseases and other chronic conditions in the country. Growing aging population base, along with many initiatives taken by the government of India to expand the provision of vaccines in the nation, will positively influence business development. Companies operating in the vaccines market are concentrating on gripping untapped market potential in the country, thereby pushing the market development.

Moreover, the growth of new and improved immunizations for several diseases is a major factor predictable to push growth. The occurrence of several pipeline drugs is expected to lead the development of the Vaccine Market.

The surge in the occurrence of infectious diseases in France, including measles, has stimulated the demand for vaccines in the country after high CAGR during the forecast period. Furthermore, many labors assumed by the French health bodies to make mindfulness about vaccines through social media platforms, including LinkedIn, Facebook, Twitter, have motivated the acceptance of vaccines in France.

North America accounted for a significant portion of the vaccine market in 2018. The large share of North America in the global vaccines market is credited to the high occurrence of infectious diseases and growing savings by government and non-government organizations for vaccine development. On the other hand, the market in Asia is predicted to list the highest growth during the prediction period. Factors such as the growing healthcare spending and growing disposable income, government initiatives, and the occurrence of a large patient people are motivating the growth of the vaccine market in Asia.

The Asia Pacific region is predictable to bystander the firmest development over the prediction period, credited by the rising target people base with high-unmet clinical needs. In addition, the growing disposable income level and the increasing mindfulness regarding the merits of vaccination in emerging economies of the Asia Pacific region are further predictable to foster market development.

Growth Drivers

Increase in incidence of both viral and bacterial infectious diseases

An escalation in communicable diseases universal, including Ebola, influenza, swine flu, hepatitis, tuberculosis, diphtheria, and meningococcal and pneumococcal diseases, is one of the chief drivers of market growth. Vaccinations are essentially administered to people of different age groups, which strengthens their resistant system during a lifetime and offers protection against dissimilar types of infectious diseases-besides, emerging vaccines (Zika vaccines, dengue vaccines, cancer vaccines, and others), making of technologically advanced vaccines, advancements in vaccine delivery devices, and increase in immunization programs addition the market growth.

Strong Supply backed up by Robust R&D to drive the Vaccines Market

One of the vital and noteworthy drivers for market growth is the growing source of vaccines crosswise the sphere to meet the unmet needs and abide by the immunization policies to eradicate widespread diseases. Pharmaceutical companies, government foundations, international organizations, and hospitals are strongly absorbed in providing cost-effective and regular vaccination to people universal. A government investigation in all the countries has become active in safeguarding that suggested Vaccines at a minimum cost or no cost vaccinate every individual.

Table of Contents

1. Research Framework

  • 1.1. Research Objective
  • 1.2. Product Overview
  • 1.3. Market Segmentation

2. Research Methodology

  • 2.1. Qualitative Research
    • 2.1.1. Primary & Secondary Sources
  • 2.2. Quantitative Research
    • 2.2.1. Primary & Secondary Sources
  • 2.3. Market Breakdown & Data Triangulation
    • 2.3.1. Secondary Research
    • 2.3.2. Primary Research
  • 2.4. Breakdown of Primary research respondent, By Region
  • 2.5. Assumption & Limitation

3. Executive Summary

4. Global Vaccine market Industry Insights

  • 4.1. Industry Value Chain Analysis
  • 4.2. DROC Analysis
    • 4.2.1. Growth Drivers
    • 4.2.2. Restraint
    • 4.2.3. Opportunities
    • 4.2.4. Challenges
  • 4.3. Technological Landscape/Recent Development
  • 4.4. Regulatory Framework
  • 4.5. Company Market Share Analysis, 2019
  • 4.6. Porter's Five Forces Analysis
    • 4.6.1. Bargaining Power of Suppliers
    • 4.6.2. Bargaining Power of Buyers
    • 4.6.3. Threat of New Entrants
    • 4.6.4. Threat of Substitutes
    • 4.6.5. Intensity of Rivalry
  • 4.7. Impact of COVID 19

5. Global Vaccine market Overview

  • 5.1. Market Size & Forecast by Value, 2016-2026
    • 5.1.1. By Value (USD Million)
  • 5.2. Market Share & Forecast
    • 5.2.1. By Technology
      • 5.2.1.1. Live
      • 5.2.1.2. Toxoid
      • 5.2.1.3. Recombinant
    • 5.2.2. By Disease
      • 5.2.2.1. Pneumococcal
      • 5.2.2.2. Influenza
      • 5.2.2.3. DTP
      • 5.2.2.4. Rotavirus
      • 5.2.2.5. TT
      • 5.2.2.6. Polio
      • 5.2.2.7. MMR
      • 5.2.2.8. Varicella
      • 5.2.2.9. Dengue
      • 5.2.2.10. TB,
      • 5.2.2.11. Shingles
      • 5.2.2.12. Rabies
    • 5.2.3. By Route
      • 5.2.3.1. IM
      • 5.2.3.2. SC
      • 5.2.3.3. ID
      • 5.2.3.4. Oral
    • 5.2.4. By Patient
      • 5.2.4.1. Pediatric
      • 5.2.4.2. Adult
    • 5.2.5. By Region
      • 5.2.5.1. North America
      • 5.2.5.2. Europe
      • 5.2.5.3. Asia Pacific
      • 5.2.5.4. Latin America
      • 5.2.5.5. Middle East & Africa

6. North America Vaccine Market

  • 6.1. Market Size & Forecast by Value, 2016-2026
    • 6.1.1. By Value (USD Million)
  • 6.2. Market Share & Forecast
    • 6.2.1. By Technology
    • 6.2.2. By Disease
    • 6.2.3. By Route
    • 6.2.4. By Patient
    • 6.2.5. By Country
      • 6.2.5.1. United States
      • 6.2.5.2. Canada

7. Europe Vaccine market

  • 7.1. Market Size & Forecast by Value, 2016-2026
    • 7.1.1. By Value (USD Million)
  • 7.2. Market Share & Forecast
    • 7.2.1. By Technology
    • 7.2.2. By Disease
    • 7.2.3. By Route
    • 7.2.4. By Patient
    • 7.2.5. By Country
      • 7.2.5.1. Germany
      • 7.2.5.2. United Kingdom
      • 7.2.5.3. France
      • 7.2.5.4. Italy
      • 7.2.5.5. Spain
      • 7.2.5.6. Rest of Europe

8. Asia Pacific Vaccine Market

  • 8.1. Market Size & Forecast by Value, 2016-2026
    • 8.1.1. By Value (USD Million)
  • 8.2. Market Share & Forecast
    • 8.2.1. By Technology
    • 8.2.2. By Disease
    • 8.2.3. By Route
    • 8.2.4. By Patient
    • 8.2.5. By Country
      • 8.2.5.1. India
      • 8.2.5.2. China
      • 8.2.5.3. Japan
      • 8.2.5.4. South Korea
      • 8.2.5.5. Rest of Asia Pacific

9. Latin America Vaccine Market

  • 9.1. Market Size & Forecast by Value, 2016-2026
    • 9.1.1. By Value (USD Million)
  • 9.2. Market Share & Forecast
      • 9.2.1.1. By Technology
      • 9.2.1.2. By Disease
      • 9.2.1.3. By Route
      • 9.2.1.4. By Patient
      • 9.2.1.5. By Country
      • 9.2.1.5.1. Brazil
      • 9.2.1.5.2. Mexico
      • 9.2.1.5.3. Rest of Latin America

10. Middle East & Africa Vaccine Market

  • 10.1. Market Size & Forecast by Value, 2016-2026
    • 10.1.1. By Value (USD Million)
  • 10.2. Market Share & Forecast
      • 10.2.1.1. By Technology
      • 10.2.1.2. By Disease
      • 10.2.1.3. By Route
      • 10.2.1.4. By Patient
      • 10.2.1.5. By Country
      • 10.2.1.5.1. Saudi Arabia
      • 10.2.1.5.2. UAE
      • 10.2.1.5.3. South Africa
      • 10.2.1.5.4. Rest of Middle East & Africa

11. Company Profile (Company Overview, Financial Matrix, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Strategic Outlook) *

  • 11.1. Glaxosmithkline PLC
  • 11.2. Pfizer, Inc
  • 11.3. Merck & Co., Inc
  • 11.4. Sanofi Pasteur SA
  • 11.5. CSL Limited
  • 11.6. Emergent Biosolutions, Inc
  • 11.7. Johnson & Johnson
  • 11.8. Astrazeneca
  • 11.9. Serum Institute of India Pvt., LTD
  • 11.10. Bavarian Nordic
  • 11.11. Mitsubishi Tanabe Pharma Corporation
  • 11.12. Daiichi Sankyo Company, Limited
  • 11.13. Panacea Biotec, LTD
  • 11.14. Biological E
  • 11.15. Bharat Biotech .
  • 11.16. Other Prominent Players

* Financial details in case of unlisted companies will be available as per data availability

**The segmentation and the companies are subjected to modifications based on in-depth secondary for the final deliverable.